Wafik S. El‐Deiry

The paper identifies small molecules that induce apoptosis in BRCA1-deficient cancer cells and links PPAR beta/delta inhibition to poor survival in breast cancer patients.

This study shows TTFields increase p21 expression and induce cell death in TNBC cells, with enhanced effects when combined with talazoparib.

This study shows that combining ONC201 with ATR inhibitor ceralasertib synergistically kills ovarian cancer cells by inducing apoptosis and reducing anti-apoptotic proteins.

This study shows that combining PG3 with cisplatin enhances apoptosis in TP53-mutated HNSCC cells through ISR activation and ATF4 regulation.

This study compares genomic and epigenetic features of H3-G34R and H3-K27M mutated pediatric gliomas, identifying distinct molecular profiles and suggesting tailored therapeutic strategies.

This study shows that ONC206 and ONC212 synergize with lurbinectedin to kill pancreatic ductal adenocarcinoma cells with minimal toxicity to normal cells.

This paper shows that combining prexasertib with lurbinectedin synergistically kills small cell lung cancer cells by disrupting G2/M checkpoint responses.

The paper shows that miR-181d degradation via a PNPT1-ATR feed-forward loop increases MGMT expression variance, leading to temozolomide resistance in glioblastoma cells.

This paper shows that combining ONC201 or ONC206 with temozolomide and radiotherapy significantly extends survival in a GBM mouse model compared to single treatments.

This study shows that combining TLY012 with PD-1 inhibition reduces PDAC tumor growth in mice by enhancing proinflammatory cytokines and immune cell infiltration.

This study shows that ONC201 is effective against prostate cancer and small cell lung carcinoma cells, regardless of neuroendocrine differentiation markers or BRN2 overexpression.

This study shows p73 upregulates c-FLIP to suppress extrinsic apoptosis, and a compound degrades c-FLIP to enhance p73's antitumor effects in p53-mutant cancers.

This study shows that inhibiting ITGB6 enhances anti-tumor immune responses in mouse models of head and neck and pancreatic cancers, with potential for combination immunotherapy.

This study shows that SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), DR5, and MDM2 in cancer cells, potentially affecting tumorigenesis and chemotherapy response.

This study investigates whether neuroendocrine differentiation (NED) affects sensitivity to imipridones ONC201 and ONC206 in prostate cancer cell lines, finding differential responses based on SOX2 and BRN2 overexpression.

This study shows that combining ONC201 with enzalutamide or darolutamide synergistically reduces mCRPC cell viability and PSA levels, with in vivo anti-tumor effects.

This study investigates how senescent fibroblasts influence tumor growth and immune response, showing that targeting the p21-driven SASP and combining senolytics with cancer therapies can suppress tumor growth.

This study shows that androgen receptor inhibitors enhance NK cell-mediated killing of prostate cancer cells and sensitivity to NKG2A checkpoint blockade by upregulating HLA-E expression.